Immatics is a leading cancer immunotherapy company and the global leader in the discovery of novel targets and the development of TCR bispecifics for various types of cancer immunotherapies.

Such immunotherapies have the potential to revolutionize cancer treatment and offer patients significant improvements in the length and quality of their lives compared to today’s therapies. Our goal is to deliver a step change in cancer treatment through the introduction of novel and highly innovative new therapies that use the body’s own immune system to fight cancer.

Immatics’ partnering model is designed to generate significant value for our existing and future partners from its current pipeline of therapeutic cancer immunotherapies and from its world-leading discovery platform XPRESIDENT® enabling rapid generation of best in class cancer immunotherapeutics.

To learn more about partnering opportunities with immatics, please contact:

Immatics Biotechnologies GmbH
Business Development Group
Fraunhoferstraße 18b
82152 Martinsried/Planegg

Dr Rainer Kramer, CBO

Meet BD


February 1-3, New York, USA
-/ Immuno-Oncology 360°

March 7-8, New York, USA
-/ Cancer Progress by Defined Health

March 7-9, London, UK
-/ World ADOPT Summit 2017

March 20-22, Barcelona, Spain
-/ BioEurope Spring

April 1-5, Washington, D.C., USA
-/ AACR Annual Meeting 2017

April 24-26, Amsterdam, The Netherlands
-/ European Neoantigen Summit 2017

June 2-6, Chicago, USA
-/ ASCO Annual Meeting

June 19-22, San Diego (CA), USA
-/ BIO International Convention